Peptidyl-Prolyl Isomerase D

A cytoplasmic cyclophilin with molecular chaperoning properties. It is found along with other MOLECULAR CHAPERONES, in steroid aporeceptor complexes and plays a role in maintaining the nonnative folding-competent intermediate state of the steroid aporeceptors. The protein has the alias name cyclophilin D which is also the alias name for the related protein Peptidyl-Prolyl Isomerase F.

Also Known As:

Networked: 18 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kumar, P: 3 articles (06/2001 - 01/2001)
2.	Minchin, R F: 3 articles (06/2001 - 01/2001)
3.	Ratajczak, T: 3 articles (06/2001 - 01/2001)
4.	Ward, B K: 3 articles (06/2001 - 01/2001)
5.	Clos, Joachim: 2 articles (11/2016 - 07/2014)
6.	MacDonald, Andrea: 2 articles (11/2016 - 07/2014)
7.	Pescher, Pascale: 2 articles (11/2016 - 07/2014)
8.	Retzlaff, Silke: 2 articles (11/2016 - 07/2014)
9.	Späth, Gerald F: 2 articles (11/2016 - 07/2014)
10.	Yau, Wai-Lok: 2 articles (11/2016 - 07/2014)

Related Diseases

1.	Infections 07/01/2014 - "More importantly, cyp40-/- parasites were unable to establish intracellular infection in murine macrophages and were eliminated during the first 24 h post infection. " 11/01/2016 - "Together these data suggest that cyp40-/- parasites experience important intrinsic homeostatic stress that likely abrogates parasite viability during intracellular infection." 07/01/2014 - "donovani chaperone cyclophilin 40 (LdCyP40) for infection. " 07/01/2014 - "The Leishmania donovani chaperone cyclophilin 40 is essential for intracellular infection independent of its stage-specific phosphorylation status." 11/01/2016 - "In vitro viability assays, infection tests using macrophages, and mixed infection experiments ruled out a defect of cyp40-/- parasites in resistance to oxidative and hydrolytic stresses encountered inside the host cell phagolysosome. "
2.	Breast Neoplasms (Breast Cancer) 02/01/2001 - "Allelic loss was detected in 30% of breast carcinomas from patients heterozygous for the CyP40 marker. " 02/01/2001 - "The polymorphic marker which we characterized was useful in determining allelic loss at the CyP40 locus in breast cancer patients and when applied in these studies in conjunction with various cancer-associated gene markers, suggests that deletions in the region of the CyP40 gene might be a late event in breast tumor progression." 02/01/2001 - "The aim of this study was to determine the extent of allelic loss at the CyP40 locus in a panel of breast carcinomas using a newly characterized microsatellite marker located upstream of the CyP40 gene and then to correlate this with losses at chromosomal sites for cancer-associated genes. " 12/01/1999 - "CyP40 and FKBP52 were ubiquitously expressed in breast cancer cell lines, but there were significant differences in their pattern of expression. " 06/01/2001 - "Studies were therefore initiated to investigate the influence of estradiol on CyP40 and FKBP52 expression in MCF-7 breast cancer cells. "
3.	Neoplasms (Cancer) 02/01/2001 - "For each patient, allelic loss at CyP40 was then assessed and compared with losses at markers for various cancer-associated genes. " 02/01/2001 - "Allelic loss at CyP40 was determined from patients' matched tumor and normal breast tissue using Genescan 672 software analysis of fluorescently labeled, PAGE-separated PCR products incorporating the marker. " 02/01/2001 - "The polymorphic marker which we characterized was useful in determining allelic loss at the CyP40 locus in breast cancer patients and when applied in these studies in conjunction with various cancer-associated gene markers, suggests that deletions in the region of the CyP40 gene might be a late event in breast tumor progression." 02/01/2001 - "The aim of this study was to determine the extent of allelic loss at the CyP40 locus in a panel of breast carcinomas using a newly characterized microsatellite marker located upstream of the CyP40 gene and then to correlate this with losses at chromosomal sites for cancer-associated genes. " 04/01/2000 - "To determine cellular and molecular events responsible for enhanced growth in PP-induced liver tumors, we evaluated the relationships of WY-14,643 levels, apoptosis, mitosis and cyclophilin-40 (Cyp-40) expression in regressing tumors induced by WY-14,643, a potent PP. "
4.	Strabismus (Squint) 11/20/2013 - "Comparison of torpedo-stage embryo expression profiles to QTL map data revealed candidate FHE genes, including the Arabidopsis Cyclophilin-40 homologue SQUINT (SQN), and functional studies revealed a previously uncharacterised role for SQN in stem cell regulation. " 03/31/2009 - "Loss-of-function mutations of SQUINT (SQN)-which encodes the Arabidopsis orthologue of cyclophilin 40 (CyP40)-cause the precocious expression of adult vegetative traits, an increase in carpel number, and produce abnormal spacing of flowers in the inflorescence. " 11/04/2011 - "Binding of the cyclophilin 40 ortholog SQUINT to Hsp90 protein is required for SQUINT function in Arabidopsis." 11/04/2011 - "SQN (SQUINT) is the Arabidopsis ortholog of the immunophilin CyP40 (cyclophilin 40) and promotes microRNA activity by promoting the activity of AGO1. "
5.	Prostatic Neoplasms (Prostate Cancer) 04/14/2018 - "Cyp40 is overexpressed in prostate cancer and certain T-cell lymphomas. " 10/01/2007 - "We show that levels of FKBP52, FKBP51, Cyp40, and a related co-chaperone PP5 were much higher in prostate cancer cells lines [(LNCaP), PC-3, and DU145] compared with primary prostate cells, and that the AR of LNCaP cells can interact with Cyp40. " 03/18/2010 - "FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A."

Related Drugs and Biologics

1.	tacrolimus binding protein 4 (FKBP52)
2.	Proteins (Proteins, Gene)
3.	Immunophilins
4.	Messenger RNA (mRNA)
5.	Estradiol (Delestrogen)
6.	Estrogen Receptors
7.	Peptidyl-Prolyl Isomerase D
8.	MicroRNAs (MicroRNA)
9.	Cyclosporine (Ciclosporin)
10.	Tacrolimus (Prograf)

Related Therapies and Procedures

1.	Therapeutics